Search
May 10
In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease
CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform...
Aug 28, 2023
Learning about gene writing at Tessera Therapeutics
Tessera’s CEO explains gene writing and then we take a tour to learn about high-throughput testing, RNA purification, and LNP encapsulation.
.png){kind=logo}
